_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
